P21

P21 was developed as a minimized CNTF agonist, retaining the neurogenic and neuroprotective properties of full-length CNTF while avoiding its dose-limiting systemic toxicity (weight loss, anorexia, inflammatory activation). CNTF itself promotes adult hippocampal neurogenesis — the birth of new neurons in the dentate gyrus — which is significantly impaired in Alzheimer's disease and aging.

In transgenic Alzheimer's mouse models (APP/PS1), P21 administered by osmotic minipump increased hippocampal neurogenesis, reduced amyloid beta deposition, and reversed spatial memory deficits in Morris water maze testing. Its ability to simultaneously promote new neuron formation and reduce amyloid pathology makes it a uniquely dual-mechanism nootropic candidate.

// STAT3-MEDIATED NEUROGENESIS

P21 activates JAK/STAT3 signaling in neural stem cells of the hippocampal subgranular zone, driving proliferation and differentiation of new neurons. Increased STAT3 activity also upregulates pro-survival genes including Bcl-2 and VEGF in mature neurons.

// AMYLOID BETA CLEARANCE

P21 treatment reduces amyloid beta (Aβ42) plaque burden in mouse models, potentially by enhancing microglial phagocytosis and upregulating neprilysin and IDE (insulin-degrading enzyme) — key Aβ-degrading enzymes. Reduced Aβ burden correlates with improved cognitive performance.